An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major

Therapeutic Drug Monitoring

Volumn 21, Issue 1, 1999, Pages 74-81

  Diav Citrin, Orna ^a   Atanackovic, Gordana ^a   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Compliance; Deferiprone; Iron overload; Pharmacokinetics; Thalassemia; Vitamin C

Indexed keywords

ASCORBIC ACID; DEFERIPRONE; FERRITIN; IRON;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; HUMAN; IRON BLOOD LEVEL; LIVER LEVEL; LIVER WEIGHT; PATIENT COMPLIANCE; PRIORITY JOURNAL; THALASSEMIA MAJOR;

ADULT; ASCORBIC ACID; BETA-THALASSEMIA; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PYRIDONES; TREATMENT OUTCOME;

EID: 0033025760     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199902000-00011     Document Type: Article

References (35)

1. Kontoghiorghes GJ. Present Status and future prospects of oral iron chelation therapy in thalassaemia and other diseases. Indian J Pediatr 1993;60:485-507.
2. 1, an oral iron chelator, in transfusion dependent thalassemia: Indian trial. Br J Haematol 1992; 82:460-6.
3. 1) in thalassemia major. Blood 1992;80: 593-9.
4. Pippard MJ. Measurement of iron status. Prog Clin Biol Res 1989; 309:85-92.
5. Olivieri NF, Brittenham GM, Matsui D. et al: Iron chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995;332:918-22.
6. Cartwright GE, Edwards CQ, Kravitz K, et al. Hereditary hemochromatosis: Phenotypic expression of the disease. N Engl J Med 1979;301:175.
7. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986;6:24.
8. Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982;307:1671-5.
9. Matsui D, Klein J, Hermann C, et al. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral chelator 1,2-dimethyl-3-hydrxypyrid-4-one in patients with thalassemia. Clin Pharmacol Ther 1991;50:294-8.
10. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-7
11. Klein J, Damani LA, Chung D, et al. A high performance liquid chromatographic method for the measurement of the iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in human plasma. Ther Drug Monit 1991;13:51-4.
12. Kutnink MaA, Hawkes WC, Schaus EE, et al. An internal standard method for the unattended high-performance liquid chromatographic analysis of ascorbic acid in blood components. Anal Biochem 1987;166:424-30.
13. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival of medically treated patients with homozyous thalassemia. N Engl J Med 1994;331:574.
14. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567.
15. Tricta F, Spino M. Apparent variability of hepatic iron concentrations (HIC) during sequential assessment of thalassemia major patients (TM). Proceedings of the 25th meeting of the Italian pediatric hematology/oncology association, Pavia, Italy. 1998:213.
16. Chatterjea B, Maitra A, Banerjee DK, et al. Status of ascorbic acid in iron deficiency anaemia and thalassaemia. Acta Haematol 1980; 64:271-5.
17. Giardina PJ, Hilgartner MW. Update on thalassemia. Pediatr Rev 1992;13:55-62.
18. Hussain MA, Green N, Flynn DM, et al. Effect of dose, time and ascorbate on iron excretion after subcutaneous desferrioxamine. Lancet 1977;1:977-9.
19. Bridges KR, Hoffman KE. The effects of ascorbic acid on the intracellular metabolism of iron and ferritin. J Biol Chem 1986; 261:14273-7.
20. O'Brien RT. Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major. Ann NY Acad Sci 1974;232:221-5.
21. Nienhuis AW. Vitamin C and iron. N Engl J Med 1981;304:170-1.
22. Nienhuis AW, Griffith P, Strawczynski H, et al. Evaluation of cardiac function in patients with thalassemia major. Ann NY Acad Sci 1980;344:384-96.
23. Hider RC, Choudhury R, Rai BL, et al. Design of orally active iron chelators. Acta Haematol 1996;95:6-12.
24. Porter JB. Evaluation of new iron chelators for clinical use. Acta Haematol 1996;95:13-25.
25. 1. Lancet 1990;335:601.
26. 1). Indian J Pediatr 1993;60:509-16.
27. 1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. Br J Haematol 1990;76:550-3.
28. 1 and desferrioxamine in iron-loaded patients. Lancet 1990;336:1275-9.
29. 1). Br J Haemarol 1994;86(suppl 1):5.
30. Link G, Pinson A, Hershko C. Ability of the orally effective iron chelators dimethyl-and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells. Blood 1994;83:2692-7.
31. Al-Refaie FN, Wonke B, Hoffbrand AV. Deferiprone-associated myelotoxicity. Eur J Haematol 1994;53:298-301.
32. 1). II. Clinical observations. Br J Haematol 1990;76:301-4.
33. Berkovitch M, Laxer RM, Inman R, et al. Arthropathy in thalassaemia patients receiving deferiprone. Lancet 1994;343:1471-2.
34. Hoffbrand AV, Al-Refaie F, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91:285-300.
35. 1). Blood 1996;88: 651A.